ZHPV16E7384 treatment inhibited the expression of cyclin D1 and CDK4 to disrupt their normal cell cycle regulatory functions, leading to the cell cycle arrest at the G1/S phase in target cancer cells, which is more likely through the coordinated interactions between the cyclin D1/CDK4 and Rb/E2F1 complexes. Here, RB1 is linked to cancer.